News and Views
Nature Genetics 41, 509 - 510 (2009)
doi:10.1038/ng0509-509
TMPRSS2-ERG and PTEN loss in prostate cancer
Jeremy A Squire1
-
Jeremy A. Squire is in the Department of Pathology and Molecular Medicine and the NCIC Clinical Trials Group at Queen's University, Kingston, Ontario, Canada.
e-mail: squirej@queensu.ca
Abstract
Two studies show that the common recurrent gene fusion between TMPRSS2 and ERG promotes prostate cancer in both mouse and humans when PTEN is concurrently lost. In human prostate cancer, the presence of both these aberrations may be indicative of poor prognosis, suggesting that preclinical therapeutic research should target both of these pathways.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Prostate cancer PSA as an intermediate end point in clinical trialsNature Reviews Urology News and Views (01 Sep 2009)
RESEARCH
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics Letter (01 May 2009)
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancerBritish Journal of Cancer Original Article
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progressionModern Pathology Original Article
See all 7 matches for Research
